[A Case of a Patient with Locally Recurrent Rectal Cancer Who Underwent Surgical Resection after Chemotherapy with FOLFOXIRI plus Bevacizumab].

Abstract

A 60-year-old woman underwent intersphincteric resection for lower rectal cancer in 2016. The pathological stage was pT3N1M0, stage Ⅲa and the cancer was curatively resected. Local recurrence was detected 6 months after the surgery. The patient received chemotherapy of 4 courses of FOLFOXIRI plus bevacizumab(Bev). A Grade 4 adverse event(febrile neutropenia) occurred but the treatment was continued after a dose reduction to 80%. The size of the tumor decreased significantly after chemotherapy and posterior pelvic exenteration with sacral resection was performed. Pathological analysis revealed a positive radial margin but there were no remarkable complications after surgery and no obvious recurrence during the 9 months after the operation. Therefore, we concluded that FOLFOXIRI plus Bev chemotherapy is a manageable and useful treatment for locally recurrent rectal cancer.

• Authors: Masatoshi Shigoka, Masanobu Enomoto, Takahiro Wada, Junichi Mazaki, Hiroshi Kuwabara, Tetsuo Ishizaki, Yasunori Ishibashi, Yuichi Nagakawa, Kenji Katsumata, Akihiko Tsuchida
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 46 Issue 4 Pg. 796-798 (Apr 2019) ISSN: 0385-0684 [Print] Japan
• PMID: 31164539 (Publication Type: Case Reports, Journal Article)

Chemical References

• Organoplatinum Compounds
• Bevacizumab
• Leucovorin
• Fluorouracil
• Camptothecin

Topics

• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, therapeutic use)
• Bevacizumab (administration & dosage)
• Camptothecin (administration & dosage, analogs & derivatives)
• Female
• Fluorouracil (administration & dosage)
• Humans
• Leucovorin (administration & dosage)
• Middle Aged
• Neoplasm Recurrence, Local
• Organoplatinum Compounds (administration & dosage)
• Rectal Neoplasms (drug therapy, surgery)